keyword
MENU ▼
Read by QxMD icon Read
search

Ropinirole

keyword
https://www.readbyqxmd.com/read/28320137/what-increases-the-risk-of-malnutrition-in-parkinson-s-disease
#1
Svetlana Tomic, Vlasta Pekic, Zeljka Popijac, Tomislav Pucic, Marta Petek, Tihana Gilman Kuric, Sanja Misevic, Ruzica Palic Kramaric
Parkinson's disease (PD) patients are at a higher risk of malnutrition. The prevalence has been estimated to 0-24%, while 3%-60% of PD patients are reported to be at risk of malnutrition. To date, there is no clear explanation for malnutrition in these patients. The aim of this study was to determine the prevalence of malnutrition and to analyze factors that influence its appearance. The Mini Nutritional Assessment (MNA) was used to determine normal nutritional status; at risk of malnutrition; and already malnourished status...
April 15, 2017: Journal of the Neurological Sciences
https://www.readbyqxmd.com/read/28273839/parkinson-s-disease-from-pathogenesis-to-pharmacogenomics
#2
REVIEW
Ramón Cacabelos
Parkinson's disease (PD) is the second most important age-related neurodegenerative disorder in developed societies, after Alzheimer's disease, with a prevalence ranging from 41 per 100,000 in the fourth decade of life to over 1900 per 100,000 in people over 80 years of age. As a movement disorder, the PD phenotype is characterized by rigidity, resting tremor, and bradykinesia. Parkinson's disease -related neurodegeneration is likely to occur several decades before the onset of the motor symptoms. Potential risk factors include environmental toxins, drugs, pesticides, brain microtrauma, focal cerebrovascular damage, and genomic defects...
March 4, 2017: International Journal of Molecular Sciences
https://www.readbyqxmd.com/read/28167638/effects-of-repeated-ropinirole-treatment-on-phencyclidine-induced-hyperlocomotion-prepulse-inhibition-deficits-and-social-avoidance-in-rats
#3
Amanda M Maple, Tanessa Call, Phylicia C Kimmel, Ronald P Hammer
Phencyclidine (PCP), a noncompetitive N-methyl D-aspartate (NMDA) receptor antagonist, provides the most complete pharmacological model of schizophrenia in humans and animals. Acute PCP causes hyperlocomotion, disrupts prepulse inhibition (PPI), and increases social avoidance in rats. We previously showed that repeated treatment with the dopamine (DA) D2-like receptor agonists, quinpirole or ropinirole, prevents agonist-induced PPI disruption. The present study examines whether repeated ropinirole treatment similarly attenuates the effects of PCP in a more complete model of schizophrenia symptoms...
February 6, 2017: Journal of Pharmacology and Experimental Therapeutics
https://www.readbyqxmd.com/read/28131725/the-5-alpha-reductase-inhibitor-finasteride-reduces-dyskinesia-in-a-rat-model-of-parkinson-s-disease
#4
Roberto Frau, Paola Savoia, Silvia Fanni, Chiara Fiorentini, Camino Fidalgo, Elisabetta Tronci, Roberto Stancampiano, Mario Meloni, Antonino Cannas, Francesco Marrosu, Marco Bortolato, Paola Devoto, Cristina Missale, Manolo Carta
Levodopa-induced dyskinesia (LID) is a disabling motor complication occurring in Parkinson's disease patients (PD) after long-term l-DOPA treatment. Although its etiology remains unclear, there is accumulating evidence that LID relies on an excessive dopamine receptor transmission, particularly at the downstream signaling of D1 receptors. We previously reported that the pharmacological blockade of 5-alpha reductase (5AR), the rate limiting enzyme in neurosteroids synthesis, rescued a number of behavioral aberrations induced by D1 receptor-selective and non-selective agonists, without inducing extrapyramidal symptoms...
January 26, 2017: Experimental Neurology
https://www.readbyqxmd.com/read/28120630/a-randomized-fixed-dose-dose-response-study-of-ropinirole-prolonged-release-in-advanced-parkinson-s-disease
#5
Theresa A Zesiewicz, Stephen Chriscoe, Theresa Jimenez, James Upward, Maria Davy, Susan VanMeter
AIM: This Phase IV, double-blind, randomized, parallel-group study characterized the dose-response and tolerability of fixed doses of ropinirole prolonged release (PR) in subjects with advanced Parkinson's disease. PATIENTS & METHODS: Subjects receiving concomitant l-dopa received once-daily ropinirole PR 4, 8, 12, 16 or 24 mg, or placebo, up-titrated for 13 weeks, maintained for 4 weeks. RESULTS: At maintenance period week 4, ropinirole PR significantly reduced total awake 'Off-time' (16 mg; p = 0...
February 2017: Neurodegenerative Disease Management
https://www.readbyqxmd.com/read/28120629/a-fixed-dose-dose-response-study-of-ropinirole-prolonged-release-in-early-stage-parkinson-s-disease
#6
Theresa A Zesiewicz, Stephen Chriscoe, Theresa Jimenez, James Upward, Susan VanMeter
AIM: This Phase IV, double-blind, randomized, parallel-group study characterized the dose-response and tolerability of fixed doses of ropinirole prolonged release (PR). PATIENTS & METHODS: Subjects with early Parkinson's disease (PD) received placebo or ropinirole PR 2, 4, 8, 12 or 24 mg once daily, up-titrated to randomized or highest tolerated dose, maintained for 4 weeks. RESULTS: The primary end point was not met (change from baseline in Unified PD Rating Scale motor score)...
February 2017: Neurodegenerative Disease Management
https://www.readbyqxmd.com/read/28105645/ropinirole-in-bipolar-disorder-rate-of-manic-switching-and-change-in-disease-severity
#7
Horacio A Capote, Michelle Rainka, Erica S Westphal, Jonathan Beecher, Francis M Gengo
PURPOSE: To determine the effects of ropinirole on manic switching and disease severity in bipolar disorder. DESIGN AND METHODS: A cross-sectional survey was conducted in 23 bipolar depressed patients using ropinirole combination therapy (Young Mania Rating Scale [YMRS], Bipolar Inventory of Symptoms Scale [BISS]). Retrospective Clinical Global Impression of Change (CGI-C) and CGI-S (Severity) were captured via chart review. FINDINGS: One patient (4...
January 20, 2017: Perspectives in Psychiatric Care
https://www.readbyqxmd.com/read/27994356/a-double-blind-randomized-controlled-trial-to-compare-the-efficacy-and-tolerability-of-fixed-doses-of-ropinirole-bupropion-and-iron-in-treatment-of-restless-legs-syndrome-willis-ekbom-disease
#8
Kirti Vishwakarma, Juhi Kalra, Ravi Gupta, Mukesh Sharma, Taruna Sharma
BACKGROUND: We aimed to compare the efficacy of fixed doses of bupropion and ropinirole and iron alone for the treatment of restless legs syndrome (RLS) and to look for the tolerability of these medications. MATERIALS AND METHODS: Patients diagnosed with RLS were randomly divided into three groups with thirty patients in each group (Group A: Bupropion [300 mg/day], Group B: Ropinirole [0.25-0.5 mg/day], and Group C: Oral iron [150 mg elemental iron] along with folic acid [500 μg])...
October 2016: Annals of Indian Academy of Neurology
https://www.readbyqxmd.com/read/27930495/risk-of-gambling-disorder-and-impulse-control-disorder-with-aripiprazole-pramipexole-and-ropinirole-a-pharmacoepidemiologic-study
#9
Mahyar Etminan, Mohit Sodhi, Ali Samii, Ric M Procyshyn, Michael Guo, Bruce C Carleton
BACKGROUND: Recently, the US Food and Drug Administration issued a warning regarding the potential risk of gambling disorder, but large epidemiologic studies are lacking. METHODS: We used a large health claims database from the United States and conducted a nested case-control study. Cases were defined as subjects newly diagnosed with gambling disorder or impulse control disorder. For each case, 10 controls were selected and matched to cases by age and follow-up time and calendar time...
February 2017: Journal of Clinical Psychopharmacology
https://www.readbyqxmd.com/read/27856776/practice-guideline-summary-treatment-of-restless-legs-syndrome-in-adults-report-of-the-guideline-development-dissemination-and-implementation-subcommittee-of-the-american-academy-of-neurology
#10
John W Winkelman, Melissa J Armstrong, Richard P Allen, K Ray Chaudhuri, William Ondo, Claudia Trenkwalder, Phyllis C Zee, Gary S Gronseth, David Gloss, Theresa Zesiewicz
OBJECTIVE: To make evidence-based recommendations regarding restless legs syndrome (RLS) management in adults. METHODS: Articles were classified per the 2004 American Academy of Neurology evidence rating scheme. Recommendations were tied to evidence strength. RESULTS AND RECOMMENDATIONS: In moderate to severe primary RLS, clinicians should consider prescribing medication to reduce RLS symptoms. Strong evidence supports pramipexole, rotigotine, cabergoline, and gabapentin enacarbil use (Level A); moderate evidence supports ropinirole, pregabalin, and IV ferric carboxymaltose use (Level B)...
December 13, 2016: Neurology
https://www.readbyqxmd.com/read/27830514/development-of-eudragit-rs-100-microparticles-loaded-with-ropinirole-optimization-and-in-vitro-evaluation-studies
#11
Prince Muhammad Kashif, Asadullah Madni, Muhammad Ashfaq, Mubashar Rehman, Muhammad Ahmad Mahmood, Muhammad Imran Khan, Nayab Tahir
The current study aimed to develop novel pH independent microparticles loaded with ropinirole (ROP) for sustained drug release. Eudragit RS 100 was used as release retardant and microparticles were fabricated by oil-in-oil emulsion solvent evaporation method. A three-factor three-level Box-Behnken design using Design-Expert software was employed to optimize formulation variables. Ropinirole loaded microparticles were evaluated with respect to morphology, particle size, encapsulation efficiency, and in vitro release profile...
November 9, 2016: AAPS PharmSciTech
https://www.readbyqxmd.com/read/27819409/interventions-for-chronic-kidney-disease-associated-restless-legs-syndrome
#12
REVIEW
Seerapani Gopaluni, Mohamed Sherif, Naim A Ahmadouk
BACKGROUND: Restless legs syndrome (RLS) is defined as the spontaneous movement of the limbs (mainly legs) associated with unpleasant, sometimes painful sensation which is relieved by moving the affected limb. Prevalence of RLS among people on dialysis has been estimated between 6.6% and 80%. RLS symptoms contribute to impaired quality of life and people with RLS are shown to have increased cardiovascular morbidity and mortality.Various pharmacological and non-pharmacological interventions have been used to treat primary RLS...
November 7, 2016: Cochrane Database of Systematic Reviews
https://www.readbyqxmd.com/read/27810181/a-method-to-switch-from-oral-dopamine-agonists-to-rotigotine-in-patients-with-restless-legs-syndrome-and-mild-augmentation
#13
John W Winkelman, Susan E Mackie, Leslie A Mei, Samuel Platt, Laura Schoerning
BACKGROUND: We examined the short- and long-term efficacy and tolerability of a cross-titration algorithm from oral dopamine agonists to the rotigotine transdermal patch in patients dissatisfied with their restless legs syndrome (RLS) treatment, predominantly with mild augmentation. METHODS: Patients with RLS (n = 20) were recruited at a single site. The cross-titration consisted of decreasing oral dopaminergic agents (ropinirole by 1 mg or pramipexole by 0...
August 2016: Sleep Medicine
https://www.readbyqxmd.com/read/27796464/ergot-and-non-ergot-dopamine-agonists-and-heart-failure-in-patients-with-parkinson-s-disease
#14
François Montastruc, Florence Moulis, Mélanie Araujo, Leila Chebane, Olivier Rascol, Jean-Louis Montastruc
PURPOSE: Some studies have suggested a potential risk of heart failure in patients with Parkinson's disease receiving dopamine (DA) agonists. However, the results are conflicting. We used VigiBase®, the World Health Organization (WHO) Global Individual Case Safety Reports (ICSRs) database, to investigate a potential signal strengthening of heart failure with DA agonists in Parkinsonian patients older than 45 years. METHODS: A case/non-case (disproportionality) analysis was performed in Vigibase® using ICSRs registered between 1978 and May 2016...
January 2017: European Journal of Clinical Pharmacology
https://www.readbyqxmd.com/read/27779080/efficacy-of-ropinirole-loaded-plga-microspheres-for-the-reversion-of-rotenone-induced-parkinsonism
#15
Sofía Negro, Liudmilla Boeva, Karla Slowing, Ana Fernández-Carballido, Luis García-García, Emilia Barcia
A new controlled delivery system is developed for ropinirole (RP) for the treatment of Parkinson´s disease (PD) consisting in PLGA microparticles (MPs) which exhibited in vitro constant release of RP (78.23 µg/day/10 mg MPs) for 19 days. The neuroprotective effects of RP released from MPs are evaluated in SKN-AS cells after exposure to rotenone (20 μM). Cell apoptosis was significantly reduced by RP (100-120 μM). Daily doses of rotenone (2 mg/kg) given i.p. to rats induced neuronal and behavioral changes similar to those of PD...
September 28, 2016: Current Pharmaceutical Design
https://www.readbyqxmd.com/read/27725534/transdermal-patch-of-rotigotine-attenuates-freezing-of-gait-in-patients-with-parkinson-s-disease-an-open-label-comparative-study-of-three-non-ergot-dopamine-receptor-agonists
#16
COMPARATIVE STUDY
Ken Ikeda, Takehisa Hirayama, Takanori Takazawa, Kiyokazu Kawabe, Yasuo Iwasaki
Objective Parkinson's disease (PD) is characterized by the progressive degeneration of the nigrostriatal dopaminergic neurons. Rotigotine is a non-ergot dopamine receptor agonist (DA). Its transdermal patch maintains the effective concentrations for 24 hours. Freezing of gait (FOG) is a common and devastating symptom in PD patients. Little is known about therapeutic effects of rotigotine on FOG in PD patients. Herein we compared how three non-ergot DAs of rotigotine, pramipexole LA and ropinirole CR influence FOG, besides classical motor deficits in PD patients...
2016: Internal Medicine
https://www.readbyqxmd.com/read/27714426/chronic-administration-of-the-dopamine-d2-3-agonist-ropinirole-invigorates-performance-of-a-rodent-slot-machine-task-potentially-indicative-of-less-distractible-or-compulsive-like-gambling-behaviour
#17
Paul J Cocker, M Tremblay, S Kaur, Catharine A Winstanley
RATIONALE: Whilst dopamine agonist therapies can successfully manage the symptoms of diseases such as Parkinson's disease (PD), fibromyalgia and restless leg syndrome, they can also cause impulse control and addiction disorders such as gambling disorder (GD). These compulsive behaviours seriously undermine the utility of such treatments. OBJECTIVES: The objective of the study was to model this phenomenon using a rodent slot machine task (rSMT) in order to investigate the neurobiological basis underlying such behavioural changes...
January 2017: Psychopharmacology
https://www.readbyqxmd.com/read/27698498/prescribing-errors-with-levetiracetam-oral-solution-communicate-insulin-dose-and-concentration-on-separate-lines-risperidone-and-ropinirole-mix-ups-iv-line-disinfection-caps-can-become-foreign-bodies
#18
Michael R Cohen, Judy L Smetzer
These medication errors have occurred in health care facilities at least once. They will happen again-perhaps where you work. Through education and alertness of personnel and procedural safeguards, they can be avoided. You should consider publishing accounts of errors in your newsletters and/or presenting them at your inservice training programs. Your assistance is required to continue this feature. The reports described here were received through the Institute for Safe Medication Practices (ISMP) Medication Errors Reporting Program...
September 2016: Hospital Pharmacy
https://www.readbyqxmd.com/read/27533244/thermoreversible-mucoadhesive-in-situ-nasal-gel-for-treatment-of-parkinson-s-disease
#19
Monica Rao, Deepak Kumar Agrawal, Chaitanya Shirsath
Parkinson's disease is a degenerative disorder of the central nervous system (CNS). The most obvious symptoms are movement-related such as shaking, rigidity, slowness of movement and difficulty with walking, rigid muscular movements and difficulty in chewing and swallowing especially solid dosage forms. Ropinirole is an anti-Parkinson drug that has low oral bioavailability which is primarily due to first-pass metabolism. The objective of proposed work was to increase bioavailability of ropinirole and avoid patient discomfort by formulating thermoreversible in situ nasal gel...
September 1, 2016: Drug Development and Industrial Pharmacy
https://www.readbyqxmd.com/read/27491846/lc-ms-ms-assay-of-ropinirole-in-rat-biological-matrices-elimination-of-lysoglycerophosphocholines-based-matrix-effect
#20
Xingjin Yan, Shouwei Zhao, Wenwen Zhu, Jing Rao, Li Kang, Jiaqiang Xu, Dan Li, Lixia Qin, Lihui Qiu, Gao Li, Jiangeng Huang, Luqin Si
AIM: To adequately support PK evaluation of ropinirole in rats following intranasal administration, it was desirable to determine ropinirole concentrations in rat plasma, brain homogenate and microdialysate. Results & methodology: A robust LC-MS/MS method has been developed for the determination of ropinirole in biological samples. Liquid-liquid extraction using ethyl acetate eliminated matrix effect due to significantly reduced levels of lysoglycerophosphocholines. The assay was fully validated with dynamic ranges of 0...
September 2016: Bioanalysis
keyword
keyword
105249
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"